Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5852W HIGH $5.59
Volume
2.49 M
Value Traded
25.41 M
Short % Float
5.58%
Days to Cover
6.3
-5%Week
+5.31%1 Month
+5.19%3 Month
+72.73%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.42 B
EPS (TTM)
-0.03
P/E Ratio
-
Ent. Value
1.99 B
Total Shares
531.16 M
Float Shares
410.46 M
Insiders
22.72%
Institutions
27.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CLOV Catalyst Timeline
Dated clinical, regulatory and corporate events for Clover Health Investments, Corp
Past FDA Catalysts and PDUFA Decisions
How CLOV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Clover Health Investments, Corp is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CLOV program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Soares KarenOfficer (Chief Legal Officer) | Sell | -19,275 1,573,423 held | $4.66 | 10/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLOV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 1.27 M | 1.50 M |
CLOV Institutional Ownership Trends
CLOV Short Interest
Shares sold short, counted twice a month.
5.58%
Short % of Float
of tradable shares sold short
22.9M
Shares Sold Short
-2.3% vs prior count
6.3 High
Days to Cover
trading days of normal volume to buy every short share back
3.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLOV ranks across every disease it competes in
Competitive Position is a premium feature
See how CLOV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLOV News
-CLOV
Oct 26, 2026▼ -0.9%today
Clover Health to Participate in Upcoming UBS Global Healthcare Conference
Clover Health announced that its Interim CFO, Clay Thornton, will present at the 2026 UBS Global Healthcare Conference on November 9, 2026. The event will feature a live webcast accessible on Clover's investor relations website. Clover Health aims to enhance healthcare access for seniors through its technology platform.
Read more →-CLOV
Oct 19, 2026▲ +8.1%on this news
Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three States
Clover Health has been recognized as the Best Medicare Advantage Plans in New Jersey, Georgia, and South Carolina for 2027. The company scored highest in care continuity and preventive care, reflecting its commitment to quality healthcare. Clover's technology platform, Counterpart Assistant, supports physicians in delivering coordinated care. The plans are available to over 5 million Medicare beneficiaries across five states.
Read more →-CLOV
Oct 8, 2026Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
Clover Health announced that its PPO Medicare Advantage plans earned a 5-Star rating for 2027 from CMS, while its HMO plans received 4.5 Stars. This achievement is expected to enhance Clover's ability to provide affordable healthcare and increase membership, which has already grown by 48% year-over-year. The rating reflects improvements across various quality measures.
Read more →-CLOV
Oct 7, 2026Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
Clover Health Investments, Corp. will release its financial results for the third quarter of 2026 on November 4, 2026. The company will host a webcast at 5:00 p.m. Eastern Time to discuss its performance. Clover Health focuses on providing Medicare Advantage plans and utilizes its Clover Assistant technology to improve healthcare outcomes.
Read more →-CLOV
Oct 1, 2026Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
Clover Health announced its 2027 Medicare Advantage plans, emphasizing PPO choice and preventive care. The plans include $0 to low premium options and rank #1 nationally for clinical quality. Clover Assistant will support physicians in delivering better care. The enrollment period runs from October 15 to December 7, 2026.
Read more →-CLOV
Sep 24, 2026UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors
Clover Health appointed former U.S. Senator Robert Torricelli and Dr. Brian J. Miller to its Board of Directors. These appointments fill two vacancies and enhance the Board's expertise in healthcare policy and clinical practice. Torricelli will serve on the Audit Committee, while Miller will join the Clinical Committee, strengthening Clover's mission to improve healthcare access.
Read more →-CLOV
Aug 31, 2026Clover Health to Participate in Upcoming Investor Conferences
Clover Health announced participation in two upcoming investor conferences. Interim CFO Clay Thornton will present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026, and participate in the Deutsche Bank Healthcare Summit on September 16, 2026. The company emphasizes its commitment to enhancing healthcare access for seniors.
Read more →-CLOV
Aug 5, 2026▲ +12.6%on this news
Clover Health Reports Second Quarter 2026 Results
Clover Health reported strong financial results for the second quarter of 2026, including a GAAP Net Income of $28 million and a 48% increase in Medicare Advantage membership year-over-year. The company has raised its full-year guidance, projecting total revenues between $2.92 billion and $3.00 billion. Management expressed confidence in the 2027 outlook, attributing growth to their AI-powered Clover Assistant platform and improved cohort economics.
Read more →-CLOV
Jul 22, 2026Clover Health to Participate in Upcoming Canaccord Genuity 46th Annual Growth Conference
Clover Health announced its participation in the Canaccord Genuity 46th Annual Growth Conference. Interim CFO Clay Thornton will present on August 11, 2026. The company aims to enhance healthcare access for seniors through its technology platform, Clover Assistant, which improves clinical decision-making.
Read more →-CLOV
Jul 9, 2026▼ -5.1%on this news
Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026
Clover Health Investments, Corp. will release its financial results for the second quarter of 2026 after market close on August 5, 2026. A webcast presentation by management will follow at 5:00 p.m. Eastern Time to discuss the company's performance. Clover Health aims to enhance healthcare access for Medicare beneficiaries through its technology platform.
Read more →-CLOV
Jul 7, 2026Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
Counterpart Health reported that primary care physicians using its AI platform saw better post-hospitalization care metrics. CA-enabled doctors achieved a 33% higher rate of receiving discharge information and an 11% increase in medication reconciliation. The whitepaper linked these improvements to timely follow-up during vulnerable patient transitions.
Read more →-CLOV
May 18, 2026Clover Health (Nasdaq: CLOV) First Quarter 2026 Supplemental Q&A
Clover Health provided insights into its first quarter 2026 performance and future outlook during a supplemental Q&A session. The company reported that its Clover Assistant tool is significantly improving medical cost trends for its member cohorts and leading to margin expansion. Enrollment in Clover Care Services has surged by 90% year over year, reflecting a proactive approach to engaging higher-acuity members. Despite the positive trends, Clover highlighted the importance of integrating new members carefully and addressing potential market challenges. The company remains optimistic about achieving GAAP profitability in 2026, emphasizing long-term economic growth through improved care coordination.
Read more →-CLOV
May 6, 2026Clover Health Reports First Quarter 2026 Results
Clover Health reported strong financial results for Q1 2026, achieving a GAAP Net Income of $27 million, a significant improvement from the previous year. The company also experienced a 51% increase in Medicare Advantage membership, reaching 155,773 members. Clover anticipates meeting or exceeding its full-year financial guidance, including its first full year of GAAP Net Income profitability.
Read more →-CLOV
Apr 1, 2026Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026
Clover Health Investments, Corp. announced the departure of Chief Financial Officer Peter Kuipers, effective March 30, 2026, with Clay Thornton appointed as the interim CFO. The transition has been positioned as smooth, with Kuipers continuing in an advisory role until April 24, 2026. The company also reaffirmed its financial guidance for fiscal year 2026, highlighting confidence in its operational strategy. Both Kuipers and Clover's CEO, Andrew Toy, expressed optimism about the company’s future direction and leadership capabilities.
Read more →-CLOV
Mar 6, 2026axex991x4q25supplemental Clover Health (Nasdaq: CLOV) Fourth Quarter 2025 Supplemental Q&A
Clover Health (CLOV) held a supplemental Q&A session ahead of its fourth-quarter and full-year 2025 earnings call, inviting shareholders to ask questions about the company's outlook for 2026. CEO Andrew Toy discussed the company's unique Medicare Advantage model, emphasizing a focus on achieving positive GAAP Net Income profitability while maintaining strong membership growth. Clover Health aims to leverage its cohort maturation and technology integrations to enhance profitability moving forward, despite potential challenges in the broader Medicare Advantage landscape.
Read more →-CLOV
Mar 4, 2026▲ +8%on this newsshared move
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
Clover Health has become the first payer to go live on a CMS Aligned Network, collaborating with Kno2 to facilitate real-time patient access to clinical and claims data. This achievement demonstrates the feasibility of nationwide data exchange and aligns with CMS's vision for interoperability. The initiative is powered by Counterpart Health, enhancing care coordination for Medicare patients.
Read more →-CLOV
Feb 26, 2026Clover Health Reports Fourth Quarter Full Year 2025 Results Provides Full Year 2026 Guidance
Clover Health reported its fourth quarter and full year results for 2025, indicating a notable growth in membership and revenue. The company achieved Adjusted EBITDA profitability while expecting to continue its upward trend in 2026, with projections for substantial growth in both membership and total revenues. However, Clover also reported a significant GAAP net loss of $86 million, which raises concerns about the overall financial health despite positive operational metrics. Management expressed confidence in achieving net income profitability in 2026 through continued efficiency improvements and member growth.
Read more →-CLOV
Feb 18, 2026Clover Health to Participate in Upcoming Leerink 2026 Global Healthcare Conference
Clover Health Investments, Corp. announced that CFO Peter Kuipers will present at the Leerink 2026 Global Healthcare Conference on March 10, 2026. The event will include a live webcast and Q&A session available on their investor relations website. Clover Health aims to enhance healthcare access for Medicare beneficiaries through its technology platform.
Read more →-CLOV
Jan 14, 2026▲ +10.6%on this news
Clover Health Announces 53% Growth in Medicare Advantage Membership During AEP, Increasing to 153,000 Members as of January 1, 2026; Expects First-Ever Full Year GAAP Net Income Profitability in 2026
Clover Health reported 53% year-over-year growth in Medicare Advantage membership, reaching 153,000 members as of January 1, 2026. The company expects to achieve its first full-year GAAP net income profitability in 2026. This financial outlook relies on strong member retention and improving cohort economics. The firm also highlighted a 4.0 Star rating for its PPO plans during the payment year.
Read more →-CLOV
Jan 1, 2026pressreleasedatedj Clover Health Announces 53% Growth in Medicare Advantage Membership During AEP, Increasing to 153,000 Members as of
Clover Health has reported a significant 53% increase in its Medicare Advantage membership, reaching approximately 153,000 members as of January 1, 2026. This growth occurs during a challenging period for the industry, reflecting Clover's disciplined approach to expanding its core markets. The company anticipates achieving its first-ever full year GAAP Net Income profitability in 2026, driven by strong cohort economics and efficient operations. Clover's flagship PPO plans have achieved high clinical quality, ranking first on HEDIS metrics, supporting its strong retention rates.
Read more →About Clover Health Investments, Corp
Headquarters30 MONTGOMERY STREET, JERSEY CITY, NJ, 07302
BIOPHARMAWATCH ELITE PLUS
Trade the next CLOV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime